Lloyd Rowland - Feb 2, 2022 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role: General Counsel
Signature: /s/ Lloyd Rowland
Stock symbol: CTMX
Transactions as of: Feb 2, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/4/2022, 03:52 PM
Previous filing: Oct 26, 2021
Next filing: Jul 21, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CTMX	Common Stock	Award	$0	+22.5K	+190.82%	$0.00	34.3K	Feb 2, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTMX	Stock Option (Right to Buy)	Award	$0	+135K		$0.00	135K	Feb 2, 2022	Common Stock	135K	$4.13	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/4th of the RSUs vest annually on March 15 of each year, with the first 1/4th vesting on March 15, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
F2	Includes 22,500 RSUs.
F3	1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.